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1. Introduction 
Patients suffering from neurodegenerative diseases are known to present, in comparison to 
controls, variations on the contents of  minor and trace elements in body tissues and fluids. For 
individuals affected by Parkinson’s disease (PD), some findings, regarding brain and serum, 
are cited hereafter. BRAIN. Various brain areas were characterized for trace element levels and 
some alterations were observed in patients. Higher concentrations of aluminum were 
determined by Yasui et al. (1992) in different sites; increased levels of copper were detected by 
Riederer et al. (1989) in raphe plus reticular formation, whereas diminished amounts were 
found in substantia nigra by Rajput et al. (1985) and Dexter et al. (1989). Dexter et al. (1991) and 
Griffits et al. (1999) observed an iron enrichment in substantia nigra; regarding to zinc, Dexter 
et al. (1989) found more elevated amounts in a few areas, while Riederer et al. (1989) noticed 
lower contents in raphe formation. Variations of aluminum, copper, iron and zinc levels in 
definite brain sites of PD patients were reviewed by Speziali & Orvini (2003). SERUM.  For PD 
patients, trace element changes were observed also in serum. Several studies were carried out 
at the Italian Istituto Superiore di Sanità (ISS) by Bocca et al. (2004, 2006), Forte et al. (2004, 
2005), Alimonti et al. (2007a). A decreasing trend for aluminum was observed by Bocca et al. 
(2004) and Forte et al. (2004), as well as by Hedge et al. (2004) and Pande  et al. (2005). Copper 
resulted elevated in these last two works and in a paper by Mindadse & Tschikowani (1967); in 
other investigations, by Bocca et al. (2006),  Forte et al. (2004) and Tan et al. (2007), copper 
resulted diminished. Hedge et al. (2004), Pande  et al. (2005), Forte et al. (2005), Alimonti et al. 
(2007a)  detected lower iron concentrations, whereas Tan et al. (2007) reported a higher 
amount. In the case of zinc, a slight increase was noticed by Tan et al. (2007), whereas Hedge et 
al. (2004), Pande  et al. (2005), Forte et al. (2005), Alimonti et al. (2007a) observed a significant 
decrease. A lower mercury content was found by Gellein et al. (2008).  
From this survey, it emerges that disagreeing findings for the same element are quite 
frequent. In the case of brain, we can suppose that the discrepancies among the various 
trials are related to the different areas examined. The less expected controversial findings for 
serum stimulated us to examine the up to date knowledge about the CSF of PD subjects. We 
have already published a short review on this topic (Speziali & Di Casa, 2009). In this 
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Chapter we present in a series of tables, for the first time, all the original values retrieved, 
along with several parameters that can influence the results. Here we discuss more 
extensively the role of all the factors affecting the results, which are the parameters reported 
in the tables along with the criteria for the enrollment of subjects, the analytical procedures 
and the statistical tests used. Finally, we propose with wider completeness several 
suggestions useful for possible future studies. 
 
C = Controls 
PD = Parkinson’s disease patients 
PD (On) = PD with positive response to the 
                   therapy 
PD (On/Off) = PD without positive response 
                            to the therapy  
PDCN = PD cognitively normal patients  
PDD = PD demented patients 
SD = Standard Deviation 
M = male 
F = female  
Et-AAS = Electrothermal Atomic 
                  Absorption Spectrometry 
ICP-AES = Inductively Coupled Plasma - 
                    Atomic Emission Spectometry 
DCP-AES = Direct Current Plasma -AES 
SF-ICP-MS = Sector Field – Inductively 
                        Coupled Plasma – Mass 
                        Spectrometry 
S = significant or highly significant 
difference 
NS = non-significant difference 
Table 1. Captions for the tables 
2. Aim 
We performed an investigation on the minor and trace element amounts, available in the 
literature, regarding  the CSF of PD patients and paired controls. Our purpose was to obtain 
a comprehensive picture of the element concentrations and to verify possible imbalances in 
the CSF of the diseased individuals.  
3. Data presentation  
We considered only studies where: a) both patients and controls were examined in the same 
investigation; b) the concentration values determined were reported as numbers; c) 
statistical tests were employed to verify the significance of potential changes of element 
amounts in the CSF of patients. The scientific publications were retrieved through the data 
bank Medline along with the Personal Alert Service of Thomson Reuters, Philadelphia, PA. 
From the bibliographies of the recruited papers further references were derived. The 
concentration data we recruited in the literature were published from 1987 to 2008. Values 
of Al, Ba, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Hg,  Li, Mg, Mn, Mo, Ni, Pb, Sb, Se, Si, Sn, Sr, Tl, V, 
W, Zn and Zr were found. In Tab. 1 we set out the captions useful for all our tables. In Tab. 2 
- 11 we report the mean concentration values, along with the standard deviations; we also 
show several parameters affecting the results: number, gender and age of the subjects enrolled, 
analytical technique employed, significance of possible differences between concentration 
values for patients and controls. The simultaneous availability of all these factors allows 
scientists to evaluate immediately the reliability of each trial findings. From the tables, 
indications can be also deducted on the possibility (or not) to compare directly the results of 
different trials;  increasing or decreasing element trends in patients are evident right away. 
Finally, in Tab. 12 we sum up some indications recorded in other publications of interest.  
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Ele-
ment 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y Technique
Signif-
icance 
References 
Ca 
C 
PD 
24.696 
27.911 
1.997 
4.964 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
 
ICP-AES 
NS 
Forte et al., 
2004    
 
C 
 
PD 
 
26.956   
median:  25.579 
27.312    
median:  27.301 
5.515 
 
3.385 
20 (17 M + 3 F)
 
42 (36 M + 6 F)
66.2   14.7 
 
64.5   10.7 
ICP-AES 
NS 
Alimonti et al., 
2007b 
 Mg 
C 
PD 
21.229 
20.913 
3.160 
2.024 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
 
ICP-AES 
NS 
Forte et al., 
2004    
 
C 
 
PD 
 
21.868    
median:  22.665 
23.693    
median:  22.365 
3.509 
 
4.263 
 
20 (17 M + 3 F)
 
42 (36 M + 6 F)
 
66.2   14.7 
 
64.5   10.7 
 
ICP-AES 
NS 
Alimonti et al., 
2007b 
Table 2. Calcium and magnesium in Controls and Patients (mg/L) 
 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y (Range) Technique
Signif-
icance 
References 
C 
PD tot 
PD untreated 
PD treated 
 
75.9 
181 
28.3  
266.4 
153.6 
75.1 
141.5* 
183.6 
22 (20 M + 2 F)
11 (10 M + 1 F)
6 
5 
age-matched 
64.9 (49-78) 
63.1 (49-78) 
67    (59-77) 
 
Et-AAS 
 
 
 
 
 
NS 
NS 
NS 
Gazzaniga et al., 
1992 
C 
PD 
210 
170 
150 
170 
37 (16 M + 21 F)
37 (14 M + 23 F)
62.4  17.8 
65.7  8.8 
Et-AAS  
NS 
Jiménez-Jiménez et 
al., 1998 
C 
PD 
73.3 
33.0 
72.7 
29.4 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
 
ICP-AES  
NS 
Forte et al., 2004 
C 
PD (On) 
PD (On/Off) 
237 
345 
397 
37 
47 
50 
21 (13 M + 8 F)
17 (10 M + 7 F)
19 (13 M + 6 F) 
62  11 
70  15 
72  17 
Et-AAS  
S  
S  
Qureshi et al., 2005 
and 2006 
C 
PD 
45.0 
28.2 
30.2 
14.6 
18 (10 M + 8 F)
91 (64 M + 27 F)
63.8  13.8 
65.5  9.7 
 
ICP-AES  
S  
Bocca et al., 2006 
C 
 
   
PD 
35.5 
median:  36.8
 
28.2 
median:  24.4
5.03 
 
 
14.6 
20 (17 M + 3 F)
 
 
42 (36 M + 6 F) 
66.2   14.7 
 
 
64.5   10.7 
ICP-AES  
 
 
S  
 
Alimonti et al., 
2007b 
 these two values are incoherent 
Table 3. Iron in Controls and Patients (µg/L) 
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4. Considerations on factors influencing the results  
As already pointed out in the Introduction, many factors affect the results,  conditioning 
then the comparability among the findings of the various studies. We describe now in 
details the influence of each factor as it emerged in the examined publications. 
4.1 Criteria for subject enrollment  
4.1.1 Health conditions 
In the subject enrollment, the criteria for inclusion/exclusion are fundamental and should 
absolutely include health conditions along with age and gender. Ideally, exposures due to 
environmental pollution or occupational activities and diet should also be considered. 
In the reviewed papers, only a few  teams give full details of the selection criteria used. The 
researchers of the Italian Istituto Superiore di Sanità  (ISS), Bocca, Forte, Alimonti and 
coworkers, along with the Spanish scientists (Jiménez-Jiménez et al. 1998 and Aguilar et al. 
1998) are among the few authors who describe extensively the criteria employed. The 
diseases affecting the individuals recruited as patients or controls are often not precisely 
described, mainly in the less recent works. In some publications, incongruities appear 
within the text or among the text and the data presented in the tables. It is not always clear 
whether the patients were affected by comorbidities. Due to the fact that severe illnesses of 
heart, liver, kidney and  also tumors are known to affect the levels of trace elements in 
human fluids and tissues, an exhaustive health report is also necessary in the case of  
controls. For these subjects, very heterogeneous situations have been observed. In Bourrier-
Guerin et al. (1985) - see Tab. 12 - controls were not enrolled at all. Mindadse & Tschikowani 
(1967) - see Tab. 12 - employed blood donors. In Qureshi et al. (2005, 2006) control 
individuals, simply defined “healthy”, were affected by tension headache, ischemic 
cerebrovascular disease or polyneuropathy. The Spanish group selected “healthy” subjects 
with suspected subarachnoid  hemorrhage or pseudotumor cerebri, oculomotor palsies, etc. 
The scientists of the ISS enrolled individuals not suffering from any central neurological 
disease. Kjellin (1967a and 1967b -  see Tab. 12) assumed psychoneurotic outpatients as 
representative of the “normal” condition. It is evident that, in the diverse investigations, 
were enrolled as controls subjects in really different health conditions. It is worth 
considering that, differently from blood, the samples of CSF are not easily available; 
therefore, the control specimens are mostly withdrawn from subjects undergoing lumbar 
puncture for clinical analyses. In the case of patients, the differences among the groups 
enrolled in the diverse studies are amplified by some clinical variables, as duration and 
severity of the disease along with  medical treatments and possible comorbidities. 
Regarding duration and severity of the disease, in the trial by Aguilar et al. (1998) Se and Cr 
levels showed no correlation with age at onset and duration of the illness. On the other 
hand, Alimonti et al. (2007b) detected in patients a negative association of Cr amount and 
severity and duration of the illness; in the same study, Pb appeared to be negatively related 
to the severity of the disorder, while Sn resulted to be negatively associated with the 
duration of the disease. The authors also found that age at onset did not affect the 
concentration of  Fe and of the other elements that resulted significantly different between 
controls and patients (Co, Cr, Pb, Si, Sn). Bocca et al. (2006) observed that duration and 
severity of the disease appeared not to be correlated with Al, Ca, Cu, Fe, Mn, Si and Zn 
amounts; on the other hand, Mg level decreased with the duration and severity of the 
illness. Concerning medical treatments, the therapies followed by patients are described by 
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Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y 
(Range) 
Technique
Signif-
icance 
References 
C 
PD 
19.2 (range: 10 – 33) 
18.7 (range: 7 – 30) 
5.8 
6.3 
21 
16 
 DCP-AES 
NS 
Belliveau et al., 
1990    
C 
PD tot 
PD untreated 
PD treated 
64.9 
67.7 
63.2 
67.0 
14.4 
19.9 
11.5 
18.5 
22 (20 M + 2 F) 
11 (10 M + 1 F) 
6 
5 
age-matched
64.9 (49 – 78)
63.1 (49 – 78)
67    (59 – 77)
Et-AAS 
NS 
NS 
NS 
Gazzaniga et al., 
1992 
C 
PD  
109.1 
104.9 
88.2 
86.3 
37 (16 M + 21 F) 
37 (14 M + 23 F) 
62.4  17.8 
65.7  8.8
Et-AAS 
NS 
Jiménez-Jiménez 
et al., 1998    
C 
PD 
 
22.5 
23.7 
4.76 
10.5 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
ICP-AES 
NS Forte et al., 2004   
C 
PD (On) 
PD (On/Off) 
132 
119 
109 
17 
18 
19 
21 (13 M + 8 F) 
17 (10 M + 7 F) 
19 (13 M + 6 F) 
62  11 
70  15 
72  17
Et-AAS 
NS 
NS 
Qureshi et al., 
2005 and 2006    
C 
PD 
21.9 median: 2.2 
19.4 median: 17.0
4.77 
7.97 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7
ICP-AES 
NS 
Alimonti et al., 
2007b 
C 
PDCN 
PDD 
19.6   
17.4   
10.0   
1.3 
4.3 
1.1 
32 
12 
5 
85.2   1.0 
85.3   1.4 
78.6   2.2
 
NS 
NS 
Sparks et al., 
2008   
Table 4. Copper in Controls and Patients (µg/L) 
many authors, as Gazzaniga et al. (1992), Qureshi et al. (2005, 2006), Aguilar et al. (1998), 
Jimenez-Jimenez et al. (1998),  Bocca et al. (2004, 2006), Forte et al. (2004), Alimonti et al. 
(2007b) along with Campanella et al. (1973) and Takahashi et al. (1994). Aguilar et al. (1998) 
carried out studies about the influence of antiparkinsonian treatment with various drugs on Se 
and Cr levels; in the entire group of PD patients, Se showed a non significant increase 
compared to controls, but the elevation attained the significance when only patients not 
treated with levodopa were considered. This interesting observation is just recorded in the 
article text. Jimenez-Jimenez et al. (1998) studied the effects of the same drugs on the 
concentrations of Fe, Cu, Zn and Mn; they did not observe any significant influence. 
Gazzaniga et al. (1992), confronting long-term levodopa treated and untreated patients, did 
not find any significant differences in the amounts of Cu, Fe and Mn. Qureshi et al. (2005, 2006) 
determined the amounts of Cu, Fe, Se and Zn in patients treated with levodopa, who were 
divided into two groups (PD On and PD On/Off), depending on the positive or negative 
response to the therapy. Fe and Se were found to be markedly higher than in controls in both 
kinds of patients; Zn resulted instead significantly reduced in both groups.  Bocca et al. (2006) 
evaluated that the type of therapy did not influence the concentrations of all the elements 
studied (Al, Ca, Cu, Fe, Mg, Mn, Si, Zn). Alimonti et al. (2007b) observed that diverse drugs 
did not affect the concentration of Fe; on the contrary, they influenced the amounts of  the 
elements which resulted significantly different between controls and patients (Co, Cr, Pb, Si, 
Sn).  Takahashi et al. (1994 - see Tab. 12) found that the Mg concentration in both untreated 
and treated (with levodopa) patients was lower than in controls. 
4.1.2 Age 
The subject age is known to influence the amounts of some elements in tissues and fluids. In 
serum, it has been documented for Cu by Ghayour-Mobarhan et al. (2005) and 
Kouremenou-Dona et al. (2006); for Se by Lopes et al. (2004). In brain, Markesbery et al. 
(1984), Ongkana et al. (2010) and Tohno et al. (2010) found age-related changes for several 
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Subjects Mean  SD 
N. of subjects 
(Gender) 
Age, y Technique
Signif-
icance 
References 
C 
PD 
170 
100 
140 
60 
37 (16 M + 21 F) 
37 (14 M + 23 F) 
62.4  17.8 
65.7  8.8 
Et-AAS 
S  Jiménez-Jiménez 
et al., 1998   
C 
PD 
32.9 
27.3 
8.85 
10.5 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
ICP-AES 
NS Forte et al., 2004   
C 
PD (On) 
PD (On/Off) 
161 
117 
96 
31 
19 
11 
21 (13 M + 8 F) 
17 (10 M + 7 F) 
19 (13 M + 6 F) 
62  11 
70  15 
72  17 
Et-AAS 
S  
S  
Qureshi et al., 
2005 and 2006    
C 
PD 
32.3 median: 33.5 
27.7 median: 27.8 
11.4 
9.01 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7 
ICP-AES 
NS 
Alimonti et al., 
2007b   
Table 5. Zinc in Controls and Patients (µg/L) 
 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y 
(Range) 
Technique
Signif-
icance 
References 
C 
PD 
0.97  
0.96  
0.34  
0.36 
29
9 
Et-AAS
NS Pall et al., 1987 
C 
PD tot 
PD untreated 
PD treated 
5.7 
5.4 
6.0 
5.4 
1.8
3.9 
1.3 
2.4 
22 (20 M + 2 F) 
11 (10 M + 1 F) 
6 
5 
age-matched
64.9 (49 - 78)
63.1 (49 - 78)
67    (59 - 77)
Et-AAS
NS 
NS 
NS 
Gazzaniga et al., 
1992 
C 
PD 
0.88 
1.20 
0.76
0.98 
37 (16 M + 21 F)
37 (14 M + 23 F) 
62.4  17.8 
65.7  8.8
Et-AAS
NS 
Jiménez-Jiménez 
et al., 1998 
C 
PD 
0.85 median: 0.91 
0.63 median: 0.54 
0.36
0.43 
13 (6 M + 7 F)
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
SF-ICP-MS
NS 
Bocca et al., 2004  
and Forte et al., 
2004  
C 
PD 
0.95 
0.69 
0.39
0.42 
18 (10 M + 8 F) 
91 (64 M + 27 F) 
63.8  13.8 
65.5  9.7
SF-ICP-MS
NS Bocca et al., 2006 
C 
PD 
0.95 median: 1.02 
0.69 median: 0.58
0.39
0.42 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7
SF-ICP-MS
NS 
Alimonti et al., 
2007b    
 data converted from nmol/L 
Table 6. Manganese in Controls and Patients (µg/L) 
elements. All authors who studied CSF and published element concentration values also for 
patients reported the mean age of each subject group; Gazzaniga et al. (1992) specified also 
the age range. Regarding element changes with age, Aguilar et al. (1998) found that Se and 
Cr levels were not correlated with the age of PD patients. Bocca et al. (2006) found no Zn 
changes in patients (no data given); in controls, they observed a significant Zn increment in 
subjects elder than 70 years in comparison with younger individuals, but these differences 
disappeared in patients. 
4.1.3 Gender 
This parameter also influences trace element levels. For changes of Se, Cu and Zn in serum, 
see Lopes et al. (2004) and Ghayour-Mobarhan et al. (2005). For Zn variations in brain, see 
Ongkana et al. (2010). Regarding CSF, Bocca et al. (2006) noticed lesser Fe amounts in PD 
males than in females, whereas the opposite was found in controls. They also report that Si 
concentration resulted significantly lower in patients than in controls and that in PD females 
it was  two-times lower than in  males. This remarkable observation could come out because 
the authors calculated distinct values, not published, for the two genders. 
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Ele- 
ment 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y Technique
Signif- 
icance 
References 
Cr C 
PD 
14.6  
14.5  
6.3 
7.4 
43 (19 M + 24 F) 
28 (11 M + 17 F ) 
65.2  13.0 
65.5   9.1 
Et-AAS 
NS 
Aguilar et 
al., 1998    
 C 
PD 
1.39 median: 1.47 
0.60 median: 0.54 
0.64 
0.47 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
SF-ICP-MS 
S  Bocca et al., 2004    
 C 
PD 
1.28 median:  1.39 
0.65 median:  0.55 
0.59 
0.46 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7 
SF-ICP-MS 
S  Alimonti et al., 2007b 
Se C 
PD 
13.5  
17.9  
8.2 
12.3 
43 (19 M + 24 F) 
28 (11 M + 17 F ) 
65.2  13.0 
65.5   9.1 
Et-AAS 
NS 
Aguilar et 
al., 1998 
 C 
PD (On) 
PD (On/Off) 
14.2 
19.7 
22.7 
1.8 
1.9 
2.1 
21 (13 M + 8 F) 
17 (10 M + 7 F) 
19 (13 M + 6 F) 
62  11 
70  15 
72  17 
Et-AAS 
S  
S  
Qureshi et 
al.,  2006 
Table 7. Chromium and selenium in Controls and Patients (µg/L) 
 
Ele- 
ment 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y Technique
Signif- 
icance 
References 
Pb C 
PD 
1.06 median: 1.0 
0.42 median: 0.30 
0.34 
0.38 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
SF-ICP-MS 
S  Bocca et al., 2004    
 C 
PD 
0.91 median: 0.84 
0.46 median: 0.43 
0.36 
0.24 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7 
SF-ICP-MS 
S  Alimonti et al., 2007b 
Si C 
PD 
105 
66.9 
39.3 
49.7 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
ICP-AES 
S  Forte et al., 2004    
 C 
 “ 
PD  
  “ 
  “ 
95.0 
92.5 
58.4  
63.9 
28.9 
38.0 
44.3 
44.8 
46.5 
13.7 
18 (10 M + 8 F) 
1 F 
91 (64 M + 27 F) 
1 M 
1 F 
63.8  13.8 
 
65.5  9.7 
 
 
ICP-AES  
 
S  
S  
S  
Bocca et al., 
2006    
 
 C 
PD  
95.0 median:  96.3
58.4 median:  52.3
38.3 
44.8 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2  14.7 
64.5  10.7 
ICP-AES 
S  Alimonti et al., 2007b 
 For gender difference, see text (section 4.1.3 Gender) 
Table 8. Lead and silicon in Controls and Patients (µg/L) 
4.1.4 Number of subjects examined 
In the reviewed papers, the authors usually publish the total number of controls and 
patients, and even the numbers of males and females; however, they frequently do not 
report the information actually needed, that is the number of individuals really tested for 
each element. In our review, we observed that Be, Cd, Hg, and V were determined in two 
investigations by the team of ISS (Bocca et al. 2004 and Alimonti et al. 2007b). In the 
previous one, where a lower number of individuals was considered, the element decrements 
in patients were evaluated as significant; in the second trial, where more subjects were 
enrolled, the variations came out to be not significant. Fe resulted decreased in patients at 
the limits of significance (p = 0.052) in a trial carried out by Forte et al. (2004); in two 
successive investigations by the same team (Bocca et al. 2006 and Alimonti et al. 2007b), with 
a higher number of individuals, Fe was found to be significantly reduced. The control and 
patient groups of successive trials by the same authors probably included the corresponding 
groups already examined in the previous ones; the disagreeing findings could be due to the 
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Ele- 
ment 
Subjects Mean SD 
N. of subjects 
(Gender) 
Age, y Technique
Signif- 
icance 
References 
Co C 
PD 
0.15 median: 0.16 
0.04 median: 0.03 
0.04 
0.04 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
SF-ICP-MS 
S  Bocca et al., 2004    
 C 
PD 
0.13 median: 0.13 
0.09 median: 0.06 
0.05 
0.09 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7 
SF-ICP-MS 
S  Alimonti et al., 2007b 
Ni C 
PD 
8.01 median: 7.54 
4.37 median: 1.07 
1.39 
5.61 
13 (6 M + 7 F) 
26 (24 M + 2 F) 
63.8  13.7 
64.9  10.8 
SF-ICP-MS 
NS 
Bocca et al., 
2004    
 C 
PD 
5.40 median: 6.44 
3.34 median: 1.53 
3.33 
3.61 
20 (17 M + 3 F) 
42 (36 M + 6 F) 
66.2   14.7 
64.5   10.7 
SF-ICP-MS 
NS 
Alimonti et al., 
2007b 
Table 9. Cobalt and nickel in Controls and Patients (µg/L) 
 
Ele- 
ment 
Subjects Mean SD 
N. of subjects
(Gender) 
Age, y Technique
Signif-
icance 
References 
Be C 
PD 
0.87 median: 0.85 
0.44 median: 0.44
0.33 
0.13 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
SF-ICP-MS
S  Bocca et al., 2004    
 C 
PD 
0.70 median: 0.55
0.56 median: 0.54
0.37 
0.21 
20 (17 M + 3 F)
42 (36 M + 6 F)
66.2   14.7 
64.5   10.7 
SF-ICP-MS
NS 
Alimonti et al., 
2007b   
Cd C 
PD 
0.06 median: 0.06
0.03 median: 0.03
0.02 
0.01 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
SF-ICP-MS
S  Bocca et al., 2004    
 C 
PD 
0.05 median: 0.05
0.04 median:  0.4
0.03 
0.02 
20 (17 M + 3 F)
42 (36 M + 6 F)
66.2   14.7 
64.5   10.7 
SF-ICP-MS
NS 
Alimonti et al., 
2007b  
Hg C 
PD 
1.20 median: 1.19
0.67 median: 0.74
0.50 
0.32 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
SF-ICP-MS
S  Bocca et al., 2004    
 C 
PD 
1.05 median: 0.85
0.73 median: 0.81
0.46 
0.32 
20 (17 M + 3 F)
42 (36 M + 6 F)
66.2   14.7 
64.5   10.7 
SF-ICP-MS
NS 
Alimonti et al., 
2007b 
V C 
PD 
0.12 median: 0.11
0.07 median: 0.08
0.06 
0.03 
13 (6 M + 7 F) 
26 (24 M + 2 F)
63.8  13.7 
64.9  10.8 
SF-ICP-MS
S  Bocca et al., 2004    
 C 
PD 
0.09 median: 0.10
0.07 median: 0.07
0.03 
0.03 
20 (17 M + 3 F)
42 (36 M + 6 F)
66.2   14.7 
64.5   10.7 
SF-ICP-MS
NS 
Alimonti et al., 
2007b 
Table 10. Berillium, cadmium,  mercury and vanadium in Controls and Patients (µg/L) 
different number of the considered subjects. In the case of Co, Cr, Pb and Si, the outcomes 
for significance are always the same when the number of subjects, in both control and 
patient groups, is either lower or higher. We wonder whether the changes in patients of 
these elements are so marked that result noticeable in every case. As a general consideration, 
it is obvious that the higher is the number of the subjects examined, the higher is the 
representativeness of the results obtained. 
4.2 Analytical procedures 
When determining elements at trace levels,  the entire analytical process is critical. Sampling 
and storage should be carried out in an appropriate way to minimize contamination and 
losses, following the recognized requirements in the field. The chemical treatments needed 
by each method should be as standardized as possible. The analytical technique employed 
must assure high sensitivity and good reproducibility.   
In the reviewed studies, the preanalytical steps were described with more or less details; the 
techniques employed were cited by all authors, except Sparks et al. (2008). A careful 
description of the method is generally available in the most recent papers, that sometimes refer 
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to previous publications. The techniques used for the most studied elements were principally 
electrothermal  atomic absorption spectrometry (Et-AAS) and inductively coupled plasma 
atomic emission spectrometry (ICP-AES). For some elements, sector field  inductively coupled 
plasma mass spectrometry (SF-ICP-MS) was also employed by the team of ISS. All these 
analytical techniques are widely used for trace element determination in human samples. 
 
Element Subjects Mean SD Median Significance 
Al 
C
PD 
2.64
2.15 
0.51
1.03 
2.72
2.05 
NS 
Ba 
C
PD 
0.35
0.26 
0.15
0.13 
0.31
0.24 
NS 
Bi 
C
PD 
0.10
0.08 
0.07
0.05 
0.09
0.06 
NS 
Li 
C
PD 
0.52
0.82 
0.13
0.53 
0.52
0.65 
NS 
Mo 
C
PD 
0.45
0.33 
0.27
0.17 
0.43
0.27 
NS 
Sb 
C
PD 
0.08
0.06 
0.02
0.04 
0.09
0.07 
NS 
Sn 
C
PD 
0.32
0.26 
0.07
0.11 
0.31
0.24 
S  
Sr 
C
PD
30.0
24.6
8.69
8.66
27.7
22.6
NS 
Tl 
C
PD 
0.01
0.01 
0.01
0.007 
0.01
0.01 
NS 
W 
C
PD 
0.04
0.03 
0.02
0.02 
0.04
0.03 
NS 
Zr 
C
PD 
0.06
0.04 
0.05
0.03 
0.06
0.04 
NS 
N. of subjects (Gender) 
 
C   20 (17 M + 3 F) 
PD   42 (36 M + 6 F) 
 
Technique:
Age, y
 
66.2   14.7 
64.5   10.7 
 
SF-ICP-MS 
Table 11. Other trace elements in Controls and Patients  (µg/L); (modified from Alimonti et 
al., 2007b) 
4.3 Statistical tests 
In this kind of studies, statistical tests of various types are required for diverse appraisals. 
Within each study and for each element considered,  tests are applied at first to evaluate 
whether the concentrations found for controls and patients are significantly different or not. 
In the same trial, other tests can reveal non negligible dissimilarities among the control and 
patient groups, regarding one or more factors affecting the results. When a significant 
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discrepancy is disclosed, the comparison between the mean concentration values  for 
controls and those for patients results rather inappropriate.  
A crucial point, worth of a close investigation by the scientists of the field, is to assess at 
what extent the outcomes for significance of the various tests applied are the same. When 
comparing the results of different investigations, the diversity of  the statistical tests applied 
in each one causes an amplification of the general inhomogeneity. 
In the reviewed papers, the statistical tests used to verify the difference between  the results 
for controls and patients are generally indicated. Some authors checked also possible 
differences, for one or more variability factors, among the various subject groups; their 
information is therefore more accurate.   
5. Summary of the retrieved data 
The retrieved data are non numerous, being the withdrawal of the fluid unpleasant; the 
control samples are taken from individuals undergoing lumbar puncture for neurological 
exams. Some values  have been found for Cu, Fe, Mn and Zn, whereas only few results have 
been retrieved for Cr and Si. As far as other elements are concerned, the data are absolutely 
scarce or determined only once,  mainly by the scientists of ISS.  
Examining the collected values, regarding copper - see Tab. 4 - no significant variations for 
patients as compared to controls were found in trials performed by diverse teams; 
nevertheless, in other papers (not showing analytical data for Cu), Pall et al. (1987) and Pan 
et al. (1997) - see Tab. 12 - assess to have observed a remarkable elevation. In the case of 
manganese too – see Tab. 6 - no changes were observed in the different investigations; of 
note, the levels determined by Gazzaniga et al. (1992) are higher than those found by the 
other author groups. Concerning calcium and magnesium - see Tab. 2 - no significant 
alterations are reported; however,  Takahashi et al. (1994) - see Tab. 12 - assess to have found 
a lesser Mg level in patients. As for zinc - see Tab. 5 - Forte et al. (2004) and Alimonti et al. 
(2007b) observed in PD a slight diminution, which in the trials by Jiménez- Jiménez et al. 
(1998) and Qureshi et al. (2005 and 2006) attained the significance. Aguilar et al (1998) found 
for PD subjects a non significant selenium increment - see Tab. 7; a  significant elevation 
resulted instead in all the patients, with both positive and negative response to the therapy, 
enrolled by Qureshi et al. (2006). Lead - see Tab. 8 - was found to be significantly reduced in 
patients by the team of ISS (Bocca et al. 2004 and Alimonti et al. 2007b), that obtained the 
same finding also for silicon (Forte et al. 2004, Bocca et al. 2006,  Alimonti et al. 2007b) - see 
Table 8. In the case of iron - see Tab. 3 - the most interesting element for PD, discordant 
results were unfortunately recruited. A significant depletion was found by Bocca et al. 2006 
and Alimonti et al. 2007b; for a detailed description, see the paragraph 4.1.4. An elevation, 
also significant, was seen by Qureshi et al. (2005 and 2006); other scientists as  Gazzaniga et 
al. (1992) and Jiménez- Jiménez et al. (1998) did not observe noticeable variations. The values 
determined by the ISS team appear to be remarkably lower than those published by the other 
groups. Dealing with chromium - see Tab. 7 - Aguilar et al. (1998) found similar amounts in 
the CSF of patients and controls; differently, Bocca et al. (2004) and Alimonti et al. (2007b) 
obtained much lower values and noticed a significant decrement in patients. Al, Ba, Be, Bi, Co, 
Li, Mo, Ni, Sb, Sn, Sr, Tl, V, W and Zr were determined only by the scientists of ISS - see Tab. 
9, 10, 11. No variations were observed, except significant decreases of Co and Sn. Regarding 
the results for Be and V, see the paragraph  4.1.4, where are described also the findings for Cd 
and Hg; the values for these last four elements are shown in Tab. 10.  
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Bourrier-Guerin et al. 1985 report values for 13 elements in 70 patients (34  M and 36 F) 
affected by different neurodegenerative diseases; patients were grouped all together. Si 
and Zn resulted to be significantly higher in men than in women. 
 
 
Campanella et al. 1973 enrolled 18 individuals (5 controls; 7 untreated patients; 6 patients 
treated with dopaminergic drugs), age  39 y, no gender given. They published the Cu 
mean amount found for each subject. For both patients groups, the range of the mean 
values was wider than for controls. 
 
 
Kjellin 1967a and 1967b reported Cu and Fe amounts in the CSF of a female patient (69 y) 
suffering from parkinsonism. 
Cu and Fe resulted respectively higher and lesser in comparison to a unique control, who 
was probably in both cases a male of 65 y. 
 
 
Mindadse & Tschikowani 1967 found that Au amount in PD patients was 66 µg/g,  
about the double than in controls.  The Au concentration  in controls (blood donors) is 
however not reported. 
 
 
Pall et al. 1987 found in patients (24) with untreated, idiopathic PD, a higher Cu 
concentration than in controls (34) with  various other neurological diseases. For Fe, they 
did not observe a difference between patients (26) and controls (33). 
 
 
Pan et al. 1997 observed that Cu increased significantly in PD patients; on the other hand, 
the amounts of Cd, Fe, Mn and Zn did not change. 
 
 
Takahashi et al. 1994 evaluated Br, Cu, Fe, Se, Zn and Mg levels in  25 controls and 20 PD 
patients (13 untreated and 7  treated with L-dopa). The mean Mg concentration in both 
treated and untreated parkinsonians was found to be lower than in controls. 
 
 
Woodbury et al. 1968 determined in one PD patient a Mg amount overlapping the mean 
value found for controls (11). Always in one patient, these authors determined a higher 
zinc concentration than in controls (2).  
 
Table 12. Additional information 
6. Conclusion 
Regarding  the matrix CSF, the first remark we make is that the element concentration 
values available in the literature are non numerous, probably due to the rareness of the 
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samples. Among the recruited papers, the range of values was recorded only in that by 
Belliveau et al. (1990). Knowing the ranges for controls and patients would allow to 
establish a range of normalcy for each element and, as a consequence, to individuate in 
patients a possible shift towards elevation or diminution. Examining the retrieved data, it is 
evident that for some elements the results obtained by the various research groups are of 
different levels. For Cu, the values published by the different teams vary from less than two 
decades to more than a hundred of µg/L. For Fe and Zn, the scientists of ISS determined 
concentrations much lesser than the other teams. For Cr, Aguilar et al. (1998) found values 
an order of magnitude higher than those reported by the team of ISS. The discrepancies 
regarding the element levels are difficult to explain. The mean values retrieved have often 
very large standard deviations. In the case of Be, Cd, Cr Hg, Se, Si, V,  the SDs are 
sometimes as high as the half of the mean. A similar situation resulted for Mn and Cu in the 
study by Jiménez-Jiménez et al. (1998). Dealing with Fe, Jiménez-Jiménez et al. (1998) and 
Forte et al. (2004) detected SD values very close to the mean. SDs close to the mean were also 
found for Co and Pb by the researchers of ISS; they report, for  Ni, SDs even higher.  The  
large  SDs  can  be due  to the individual  variability and/or  to the  low number  of  the 
subjects  enrolled; they are not surprising  also when the element concentration level is very 
low (a few µg/L or less). In the case of Cr and Se, and mostly in that of Fe and Si, high SDs 
are less expected. Obviously, they make it  really difficult to evaluate the significance of the 
difference among the results. 
In this review, we have verified the influence, on the results, of  number, age, gender of  the 
subjects enrolled; health conditions (with regard  also to clinical variables  as duration and 
severity of the disease and pharmacological therapies) were demonstrated to be other 
influencing factors. The importance of adequate analytical procedures and statistical tests 
has been previously described (see the respective paragraphs). 
At this point, we can suggest that, in a trial, attention should be paid to match, as far as 
possible, age and health conditions of the subjects belonging to the same group; this is more 
difficult to obtain in the case of patients.  Concerning gender, separate male and female 
groups could reveal possible unexpected information. A similar number of individuals in 
the various groups should be enrolled; anyway, we are aware that, in the clinical practice, 
the scarceness of the CSF control samples and the prevalent number of male PD patients 
(Alimonti et al. 2007b) make these requirements not always achievable. In addition, all the 
previously mentioned  factors should be not too different when confronting  the results of 
the various studies, to allow a proper comparison. It is evident that this is a truly 
unattainable task. 
In our opinion, a real upgrading in this field could actually be achieved if many specific 
indications were recorded in the single studies. Regarding every subject enrolled, 
information as age, gender, health condition, lifestyle and environmental exposure should 
be clearly reported; for each individual, also the results obtained for every element should 
be published. A detailed description of the various steps of sampling and analytical 
procedures should also be given; the single steps should be performed according to the 
indications most recently standardized.  
Following all these suggestions,  a database useful for diverse kind of investigations would 
be obtained; retrospective studies as meta-analyses, based on single factors affecting the 
results,  could be derived; even findings not detectable at the moment could arise. 
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